The biopharma industry is front-loading blockbuster drug approvals this year.
Clarivate Analytics listed the 9 blockbusters their analysts expect to see approved by the FDA this year, and only 4 of them have yet to get the green light in early Q2, including Novo Nordisk’s semaglutide, their GLP-1 drug for diabetes, and AstraZeneca’s PD-L1 checkpoint durvalumab.
It’s a new world in the payer community, and the consensus peak sales projections seem to be further off the mark than ever as the commercial kickback grows steadily worse.
